LS-P-EAST

A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications. (ABBV-400 is an antibody drug conjugate targeting c-Met with a topoisomerase 1 (Top1) inhibitor payload.)